mentioned late Tuesday it has hammered out an settlement with Thermo Fisher Scientific
for the manufacturing, labeling and packing of Moderna’s COVID-19 vaccine at a Thermo Fisher plant in North Carolina. The settlement goals “to leverage manufacturing capacity to continue to drive global supply of vaccines,” the corporate mentioned. The manufacturing of “hundreds of millions” of doses of the vaccine will begin within the third quarter, Moderna mentioned. “Thermo Fisher has been a critical partner in supplying raw materials for our COVID-19 vaccine and we are now pleased to further expand our relationship as an important manufacturing partner as well,” Moderna govt Juan Andres mentioned in an announcement. “The addition of Thermo Fisher to our network will support our efforts to scale up our manufacturing ability.” Shares of Moderna have been flat within the prolonged session Tuesday after ending the common buying and selling day down 0.2%. Thermo Fisher’s shares rose 0.7% after ending the session 4.8% decrease.